

Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir and sofosbuvir in patients with chronic hepatitis C virus (HCV) genotype 1 infection

Journal of Viral Hepatitis

25, 631-639

DOI: 10.1111/jvh.12853

Citation Report

#	ARTICLE	IF	CITATIONS
1	JNJ4178 (AL335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA1. <i>Hepatology</i> , 2019, 69, 2349-2363.	7.3	6
2	A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens. <i>Biomedicine and Pharmacotherapy</i> , 2019, 116, 108976.	5.6	4
3	Up-regulation of glycolipid transfer protein by bicyclol causes spontaneous restriction of hepatitis C virus replication. <i>Acta Pharmaceutica Sinica B</i> , 2019, 9, 769-781.	12.0	17
4	Glecaprevir/pibrentasvir for 8-weeks in treatment-naïve patients with chronic HCV genotypes 1 and 6 and compensated cirrhosis: The EXPEDITION-8 trial. <i>Journal of Hepatology</i> , 2020, 72, 441-449.	3.7	109
6	Short-duration treatment with the novel non-nucleoside inhibitor CDI31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open-label study. <i>Journal of Medical Virology</i> , 2021, 93, 3752-3760.	5.0	4
7	Required concentration index quantifies effective drug combinations against hepatitis C virus infection. <i>Theoretical Biology and Medical Modelling</i> , 2021, 18, 4.	2.1	1
8	Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis. <i>Wellcome Open Research</i> , 2019, 4, 132.	1.8	21
10	Interleukin 28B Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus Patients. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 230.	2.3	2